Efficacy of Icotinib as First-Line Therapy for 134 Patients with Advanced Lung Adenocarcinoma of Positive EGFR Mutation

于晓露,王慧敏,王韡旻,施春雷,韩宝惠,姜丽岩,潘峰,顾爱琴

DOI: https://doi.org/10.11735/j.issn.1671-170X.2017.09.B006

2017-01-01

Abstract:[Objective] To investigate the efficacy and adverse effect of icotinib as first-line therapy in treatment of patients with EGFR-mutation positive advanced lung adenocarcinoma.[Methods] One hundred and thirty four patients with EGFR-mutation positive advanced lung adenocarcinoma received oral icotinib(125mg,tid) as first-line therapy until disease progression or intolerable toxicity appeared.[Results] Among 134 patients,complete response (CR) was achieved in 6 cases (4.5％),partial response(PR) in 90 cases(67.2％),stable disease(SD) in 32 cases (23.9％) and progressive disease(PD) in 6 cases(4.5％).The ORR was 71.6％(96/134),DCR was 95.5％(128/134),mPFS was 11.2 months(95％CI:9.8～12.5months),and OS was not obtained yet.The ORR,DCR and mPFS of 19 exon muntation positive patients were 81.8％,93.5％,1 1.8months,respectively.The ORR,DCR and mPFS of 21 exon muntation positive patients were 57.9％,94.7％,10.2months,respectively.Patients with 19 exon mutation showed better ORR than those with 21 L858R mutation(81.8％ vs 57.9％,P=0.002).Non-smoking patients showed better ORR than smokers(77.4％ vs 58.5％,P=0.025).There were no significant differences in mPFS and DCR among patients of different gender,age,clinical stage,EGFR mutation state and smoking state.The main adverse effects were Ⅰ ～ Ⅱ degrees of rash(44.8％) and diarrhea(25.3％),which were generally tolerated after symptomatic treatment.[Conclusion] The results suggest that icotinib is effective for patients with EGFR-mutation positive advanced lung adenocarcinoma as first-line therapy with low and tolerated adverse effects.